The study by Liu et al. [55] demonstrated that hemizygous deletions of the ERBB4 gene were found in 33% of ChRCC cases, but not in any RO cases, indicating that ERBB4 deletions could serve as a useful marker for distinguishing between these two tumour types. This evidence concerns the gene ERBB4 and neoplasm.